HLS Therapeutics (TSE:HLS) Trading 2.2% Higher

HLS Therapeutics Inc. (TSE:HLSGet Free Report)’s stock price shot up 2.2% on Friday . The company traded as high as C$4.75 and last traded at C$4.75. 1,900 shares were traded during trading, a decline of 79% from the average session volume of 9,112 shares. The stock had previously closed at C$4.65.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. Stifel Nicolaus lowered their price target on shares of HLS Therapeutics from C$4.35 to C$4.15 in a research report on Friday, March 15th. Clarus Securities reissued a “buy” rating on shares of HLS Therapeutics in a report on Tuesday, February 6th. Finally, Raymond James cut their price target on HLS Therapeutics from C$6.50 to C$5.00 in a report on Monday, March 18th.

View Our Latest Report on HLS

HLS Therapeutics Stock Performance

The business’s fifty day moving average price is C$4.38 and its 200-day moving average price is C$4.17. The company has a debt-to-equity ratio of 89.69, a current ratio of 1.65 and a quick ratio of 1.01. The stock has a market capitalization of C$151.62 million, a PE ratio of -4.09 and a beta of 1.16.

HLS Therapeutics (TSE:HLSGet Free Report) last posted its earnings results on Thursday, March 14th. The company reported C($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of C($0.13) by C($0.05). The firm had revenue of C$21.60 million during the quarter, compared to analysts’ expectations of C$21.83 million. HLS Therapeutics had a negative return on equity of 24.69% and a negative net margin of 43.65%. As a group, equities research analysts expect that HLS Therapeutics Inc. will post -0.12 EPS for the current year.

About HLS Therapeutics

(Get Free Report)

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.

Further Reading

Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.